ClinicalTrials.gg

Program

obinutuzumab

Also written as “Obinutuzumab”, “Obinutuzumab, naptumomab estafenatox and durvalumab” and “obinutuzumab (RO5072759)”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Lymphoma, Follicular · Lupus Nephritis · Lupus Erythematosus, Systemic, led by 2 companies.

Furthest: phase 4, since Jan 24, 201935 company-led studies, 7 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche325 open or runningphase 4since Jan 24, 2019Aug 16, 2007Dec 28, 2026phase 2 · NCT04077723
AbbVie32 open or runningphase 3since May 20, 2024May 19, 2021Nov 2026phase 2 · NCT04895436

Also a collaborator on its studies: AstraZeneca and roche-pharma-ag.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 21 studies since Aug 16, 2007.

  1. Nov 3, 2015Phase 2 study in RecurrenceHoffmann-La Roche · NCT02600897 · 114 enrolled · United States, Spain, United Kingdom
  2. Dec 1, 2015Phase 2 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT02624986 · 25 enrolled · United States, Australia, Germany and more
  3. Jan 24, 2019Phase 4 study in Advanced Follicular LymphomaHoffmann-La Roche · NCT03817853 · 114 enrolled · United States, Brazil, Germany and more
  4. Mar 6, 2019Phase 1 study in Colorectal NeoplasmsHoffmann-La Roche · NCT03866239 · 47 enrolled · United States, Denmark, France and more
  5. Aug 9, 2019Phase 2 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT04077723 · 498 enrolled · United States, Australia, Belgium and more
  6. Jan 7, 2020Phase 3 study in Lupus NephritisHoffmann-La Roche · NCT04221477 · 271 enrolled · United States, Argentina, Brazil and more
  7. Feb 25, 2020Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellHoffmann-La Roche · NCT04285567 · 166 enrolled · United States, Australia, France and more
  8. Oct 27, 2020Phase 3 study in Primary Membranous NephropathyHoffmann-La Roche · NCT04629248 · 142 enrolled · United States, Argentina, Brazil and more
  9. May 19, 2021AbbVie's first study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNew to AbbVieAbbVie · NCT04895436 · 75 planned · United States, Australia, Austria and more
  10. Jul 7, 2021Phase 3 study in Lupus Erythematosus, SystemicHoffmann-La Roche · NCT04963296 · 303 enrolled · United States, Argentina, Brazil and more
  11. Sep 1, 2021Phase 2 study in Lupus NephritisHoffmann-La Roche · NCT05039619 · 40 planned · United States, Brazil, Canada and more
  12. Oct 25, 2021Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT05105841 · 20 enrolled · Japan
  13. Nov 4, 2022Phase 3 study in Nephrotic SyndromeHoffmann-La Roche · NCT05627557 · 85 enrolled · United States, Belgium, Brazil and more
  14. May 20, 2024Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT06428019 · 170 planned · United States, Australia, France and more

Ahead

  1. Nov 2026Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT04895436
  2. Dec 28, 2026Primary completion: phase 2 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT04077723
  3. Mar 2028Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellAbbVie · NCT06428019
  4. Jun 15, 2028Primary completion: phase 2 study in Lupus NephritisHoffmann-La Roche · NCT05039619

TargetBeta

MS4A1 →read by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule

Other programs on MS4A1

ProgramCompanyFurthest phaseStudies
RituximabruleHoffmann-La Rochephase 4175
ocrelizumabruleHoffmann-La Rochephase 442
ublituximabruleTG Therapeuticsphase 323
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
Anti-CD20 Monoclonal Antibody MIL62rulebeijing-mabworks-biotech-co-ltdphase 310
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
zuberitamabrulebioray-pharmaceutical-co-ltdphase 33
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28

Studies

All 35 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06428019Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more3RecruitingAbbVieMar 2028170
NCT05627557Nephrotic Syndrome · United States, Belgium, Brazil and more3CompletedHoffmann-La RocheSep 4, 202585
NCT05105841Leukemia, Lymphocytic, Chronic, B-Cell · Japan2CompletedAbbVieOct 9, 202520
NCT05039619Lupus Nephritis · United States, Brazil, Canada and more2RecruitingHoffmann-La RocheJun 15, 202840
NCT04963296Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more3Active, not recruitingHoffmann-La RocheSep 15, 2025303
NCT04895436Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more2RecruitingAbbVieNov 202675
NCT04629248Primary Membranous Nephropathy · United States, Argentina, Brazil and more3Active, not recruitingHoffmann-La RocheDec 22, 2025142
NCT04285567Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more3CompletedHoffmann-La RocheMar 19, 2024166
NCT04221477Lupus Nephritis · United States, Argentina, Brazil and more3Active, not recruitingHoffmann-La RocheAug 15, 2024271
NCT04077723Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more2Active, not recruitingHoffmann-La RocheDec 28, 2026498
NCT03866239Colorectal Neoplasms · United States, Denmark, France and more1TerminatedHoffmann-La RocheMar 13, 202447
NCT03817853Advanced Follicular Lymphoma · United States, Brazil, Germany and more4CompletedHoffmann-La RocheAug 4, 2020114
NCT02624986Lymphoma, Non-Hodgkin · United States, Australia, Germany and more2TerminatedHoffmann-La RocheMay 20, 201925
NCT02600897Recurrence · United States, Spain, United Kingdom2CompletedHoffmann-La RocheDec 15, 2021114
NCT02586051Kidney Failure, Chronic · United States1CompletedHoffmann-La RocheNov 26, 201824
NCT02550652Lupus Nephritis · United States, Argentina, Brazil and more2CompletedHoffmann-La RocheJan 15, 2019126
NCT02320487Leukemia, Lymphocytic, Chronic, B-Cell · United States2CompletedHoffmann-La RocheNov 7, 2016102
NCT02071225Leukemia, Lymphocytic, Chronic, B-Cell · Spain2CompletedHoffmann-La RocheNov 19, 201872
NCT02055820Lymphoma, Non-Hodgkin · United States, Australia, Austria and more2CompletedHoffmann-La RocheJun 28, 2017267
NCT02053610Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3CompletedHoffmann-La RocheAug 31, 2013787
NCT01998880Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3CompletedHoffmann-La RocheAug 1, 2012787
NCT01905943Leukemia, Lymphocytic, Chronic, B-Cell · Argentina, Belgium, Bosnia and Herzegovina and more3CompletedHoffmann-La RocheDec 29, 2016979
NCT01868893Leukemia, Lymphocytic, Chronic, B-Cell · United States2CompletedHoffmann-La RocheJan 201420
NCT01691898Lymphoma, Follicular · United States, Canada, France and more2CompletedHoffmann-La RocheMar 8, 2017231
NCT01685892Leukemia, Lymphocytic, Chronic, B-Cell · United States, United Kingdom1CompletedHoffmann-La RocheMay 21, 201882
NCT01680991Leukemia, Lymphoid · China1CompletedHoffmann-La RocheDec 201448
NCT01671904Leukemia, Lymphocytic, Chronic, B-Cell · United States, France, Germany1CompletedHoffmann-La RocheAug 17, 201884
NCT01414855Lymphoma, B-Cell · United States2CompletedHoffmann-La RocheDec 31, 2013100
NCT01414205Leukemia, Lymphocytic, Chronic, B-Cell · United States2CompletedHoffmann-La RocheMar 31, 201380
NCT01332968Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more3CompletedHoffmann-La RocheFeb 1, 20161,401
NCT01287741Lymphoma, Large B-Cell, Diffuse · United States, Argentina, Australia and more3TerminatedHoffmann-La RocheApr 29, 20161,418
NCT01059630Lymphoma, Non-Hodgkin · United States, Austria, Belgium and more3CompletedHoffmann-La RocheSep 30, 2014413
NCT01010061Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3CompletedHoffmann-La RocheJul 1, 2012787
NCT00576758Lymphoma, Non-Hodgkin · United States, Argentina, Austria and more2CompletedHoffmann-La RocheSep 2011175
NCT00517530Lymphoma · France, Germany2CompletedHoffmann-La RocheNov 2013134

How it is read

Names in the registry

  • “Obinutuzumab”, 35 entries
  • “obinutuzumab”, 5 entries
  • “Obinutuzumab, naptumomab estafenatox and durvalumab”, 1 entry
  • “obinutuzumab (RO5072759)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.